Details of Disease

General Information of Disease (ID: DISS2Y8A)

• Disease Name: Non-hodgkin lymphoma
• Synonyms: non-Hodgkin's lymphoma; non-Hodgkins lymphoma; non-Hodgkin's lymphoma (NHL); non-Hodgkin lymphoma; NHL
• Disease Class: 2B33: Malignant haematopoietic neoplasm
• Definition: Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.
• Disease Hierarchy:
  DISN6V4S: Lymphoma
  DISS2Y8A: Non-hodgkin lymphoma
• ICD Code:
  ICD-11: ICD-11: 2B33.5
  ICD-10: ICD-10: C82-C85
  ICD-9: ICD-9: 200, 202
  Expand ICD-9: 200202
• Disease Identifiers:
  MONDO ID: MONDO_0018908
  MESH ID: D008228
  UMLS CUI: C0024305
  MedGen ID: 6160
  HPO ID: HP:0012539
  Orphanet ID: 547
  SNOMED CT ID: 1172592001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 16 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aldesleukin	DM4YMIS	Approved	NA	[1]
Axicabtagene ciloleucel	DMYHN59	Approved	CAR T Cell Therapy	[2]
BAY 80-6946	DMLOS5R	Approved	Small molecular drug	[2]
Bortezomib	DMNO38U	Approved	Small molecular drug	[3]
Febarbamate	DMP43ST	Approved	Small molecular drug	[4]
Ibritumomab	DMG594T	Approved	Antibody	[1]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[2]
Lisocabtagene maraleucel	DMP45ME	Approved	CAR T Cell Therapy	[5]
Mitoxantrone	DMM39BF	Approved	Small molecular drug	[2]
Ofatumumab	DM295PR	Approved	Antibody	[2]
Pirtobrutinib	DMRG1X3	Approved	Small molecular drug	[6]
Plerixafor	DMCJN1P	Approved	Small molecular drug	[7]
Rituximab	DM1YVZT	Approved	Antibody	[4]
Tositumomab	DMMYZ3D	Approved	Antibody	[8]
Trofosfamide	DMHB2C3	Approved	Small molecular drug	[4]
Umbralisib	DMYRBO1	Approved	NA	[2]

This Disease is Treated as An Indication in 144 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABP 798	DMSX35S	Phase 3	NA	[9]
Adcetris	DMEDF2B	Phase 3	NA	[2]
BI-695500	DMT0NTL	Phase 3	NA	[2]
Eltoprazine	DMW6C81	Phase 3	Small molecular drug	[10]
Enzastaurin	DM5H0R9	Phase 3	Small molecular drug	[11]
Nelipepimut S	DMDBY30	Phase 3	Small molecular drug	[12]
Pixuvripixantrone	DM0NRPU	Phase 3	NA	[2]
Telcyta canfosfamide	DM94IQ3	Phase 3	NA	[13]
Imprime PGG	DMIUA3M	Phase 2/3	NA	[14]
MOR-208	DMDQOWT	Phase 2/3	Antibody	[2]
ALT-803	DMK3U1X	Phase 2	NA	[9]
AME-133v	DMIVZ3M	Phase 2	Antibody	[15]
Apilimod dimesylate	DM4N2O0	Phase 2	NA	[2]
BI-836826	DMWH7Z5	Phase 2	Antibody	[2]
CAR-T cells targeting CD19	DM28A5D	Phase 2	CAR T Cell Therapy	[16]
CAR-T cells targeting CD20	DM3RU0A	Phase 2	CAR T Cell Therapy	[16]
CAR-T cells targeting CD22	DM6XN4C	Phase 2	CAR T Cell Therapy	[16]
CAR-T cells targeting CD30	DML0KWM	Phase 2	CAR T Cell Therapy	[16]
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[17]
CC-90011	DM0EDHJ	Phase 2	Small molecular drug	[18]
CC-99282	DMX2Y51	Phase 2	Small molecule	[19]
CD19 CAR T cells	DMEK580	Phase 2	CAR T Cell Therapy	[20]
CD20 CAR T cells	DMQGI8R	Phase 2	CAR T Cell Therapy	[20]
Cerdulatinib	DMSCR2H	Phase 2	NA	[21]
CMD-003	DMLRIIP	Phase 2	NA	[22]
Coltuximab ravtansine	DMSGFOY	Phase 2	NA	[9]
CP-18770	DMX58TV	Phase 2	Small molecular drug	[23]
DCDS-4501A	DMQRCX5	Phase 2	Antibody	[24]
DI-Leu16-IL2	DMTLB92	Phase 2	Recombinant protein	[2]
G100	DMKHNXA	Phase 2	NA	[2]
GDC-0980/RG7422	DMF3MV1	Phase 2	Small molecular drug	[25]
GDC0941	DM1YAK6	Phase 2	Small molecular drug	[26]
GSK3326595	DMJRD7A	Phase 2	NA	[2]
Imexon	DM6MMRS	Phase 2	Small molecular drug	[27]
IMGN529	DMNJ491	Phase 2	Antibody	[9]
LAM-002	DMR0N74	Phase 2	NA	[28]
MT-3724	DMCNL7Z	Phase 2	Recombinant?protein	[29]
Naratuximab emtansine	DMSWUNX	Phase 2	Antibody	[30]
NIR178	DMPER4A	Phase 2	NA	[2]
SAR-3419	DMOSCBF	Phase 2	Antibody	[31]
SGN-CD19A	DMS90CU	Phase 2	NA	[32]
TT11X	DMW3M7X	Phase 2	CAR-T cell therapy	[33]
Veltuzumab	DM5BL4C	Phase 2	Monoclonal antibody	[34]
YM155	DM5Q1W4	Phase 2	Small molecular drug	[35]
90Y-labeled humanized anti-Tac mab	DMNQXZ1	Phase 1/2	Monoclonal antibody	[36]
AB-205	DMLQGXN	Phase 1/2	Cell therapy	[37]
ADG106	DM87H0S	Phase 1/2	Antibody	[38]
ALX148	DMGQX0U	Phase 1/2	Protein	[2]
ALXN2075	DM1BSD8	Phase 1/2	Small molecule	[39]
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes	DM2YTGQ	Phase 1/2	CAR T Cell Therapy	[40]
Betalutin	DMMNIU4	Phase 1/2	NA	[41]
CART30	DMLE8T9	Phase 1/2	CAR T Cell Therapy	[42]
CD19 CAR Gene Transduced T Lymphocytes	DMQJ6YL	Phase 1/2	CAR T Cell Therapy	[43]
CD19-CAR T cell	DMQE7TW	Phase 1/2	CAR T Cell Therapy	[44]
CD20-Specific CAR T Cells	DMHPZ8G	Phase 1/2	CAR T Cell Therapy	[45]
CLIC-1901	DML8US9	Phase 1/2	CAR T Cell Therapy	[46]
CTX110	DMJ7LP0	Phase 1/2	Gene therapy	[47]
Epratuzumab Y-90	DMPGHCM	Phase 1/2	Monoclonal antibody	[48]
Eptacog beta	DMTY96S	Phase 1/2	Small molecular drug	[49]
Favezelimab	DMYAIE2	Phase 1/2	Antibody	[50]
GDA-201	DMR4K0M	Phase 1/2	Cell therapy	[51]
IC9/CAR.19/IL15-transduced CB-NK cells	DMD3Y27	Phase 1/2	NA	[2]
JCAR014	DMTMVEW	Phase 1/2	CAR T Cell Therapy	[52]
JCAR017	DMJV2IF	Phase 1/2	CAR T Cell Therapy	[53]
JCARH125	DM8P7FC	Phase 1/2	CAR T Cell Therapy	[53]
MB-CART20.1	DMXU7P6	Phase 1/2	CAR T Cell Therapy	[54]
OXS-1550	DMR59D3	Phase 1/2	NA	[9]
PBCAR0191	DMJC2RU	Phase 1/2	CAR T Cell Therapy	[55]
PBCAR20A	DM7NKWQ	Phase 1/2	CAR T Cell Therapy	[56]
TC-110	DMR65X7	Phase 1/2	TCR-T cell therapy	[57]
TRBC1	DM1ZK4W	Phase 1/2	CAR T Cell Therapy	[58]
TriCAR-T-CD19	DML54PD	Phase 1/2	CAR T Cell Therapy	[59]
19-28z T CELLS	DMJ1SQY	Phase 1	CAR T Cell Therapy	[60]
ACTR087	DMW9GX0	Phase 1	NA	[2]
ACTR707	DMDIQFR	Phase 1	NA	[2]
AFM11	DMIFJZD	Phase 1	Antibody	[61]
ALLO-501	DMGIAND	Phase 1	CAR T Cell Therapy	[62]
Anti-CD19-CAR	DMWKYSM	Phase 1	CAR T Cell Therapy	[63]
Anti-CD19-CAR T cells	DMYQFCN	Phase 1	CAR T Cell Therapy	[64]
AntiCD19 CART	DMH789J	Phase 1	CAR T Cell Therapy	[65]
BAY1862864	DMM1OAL	Phase 1	NA	[2]
BM-ca	DM43RV5	Phase 1	Antibody	[66]
BTX-A51	DMC8XHQ	Phase 1	Small molecular drug	[67]
C-CAR011	DM86CZJ	Phase 1	CAR T Cell Therapy	[68]
CAR CD30 T cells	DM8NLPI	Phase 1	CAR T Cell Therapy	[69]
CAR19 T cells carrying cytoplasmic activated PD-1	DMXD4TC	Phase 1	CAR T Cell Therapy	[70]
CC-115	DMYEB5F	Phase 1	Small molecular drug	[71]
CC-90002	DMK0QDO	Phase 1	Antibody	[2]
CC-90010	DMKH3Z9	Phase 1	NA	[2]
CC-95775	DMJCIGN	Phase 1	Small molecular drug	[72]
CC-97540	DMLONJG	Phase 1	CAR T Cell Therapy	[73]
CD19 CAR T Cells	DMCUBFR	Phase 1	CAR T Cell Therapy	[74]
CD19 CAR T-cells	DMJCT6Q	Phase 1	CAR T Cell Therapy	[75]
CD19-directed CAR-T cells	DM2OEQ9	Phase 1	CAR T Cell Therapy	[76]
CD19-TriCAR-T	DMOHACZ	Phase 1	CAR T Cell Therapy	[77]
CD19.CAR-aNKT cells	DMMO2EJ	Phase 1	CAR T Cell Therapy	[78]
CD19/CD22 CAR T-Cells	DMKA2FL	Phase 1	CAR T Cell Therapy	[79]
CD20Bi aATC	DMGXS8L	Phase 1	NA	[80]
CD30 CAR T Cells	DM4VCJA	Phase 1	CAR T Cell Therapy	[81]
CD7.CAR/28zeta CAR T cells	DMHTNLJ	Phase 1	CAR T Cell Therapy	[82]
CTX-101	DMHK9WR	Phase 1	CAR T Cell Therapy	[47]
DCDS0780A	DMAJ3SI	Phase 1	NA	[2]
FSI-189	DMPENAL	Phase 1	Antibody	[83]
GDC-0349	DM3Z2JB	Phase 1	Small molecular drug	[84]
GSK461364	DM0P729	Phase 1	Small molecular drug	[85]
HH2853	DMQIE58	Phase 1	Small molecular drug	[86]
HMPL-523	DMXZ1A8	Phase 1	Small molecular drug	[87]
HMPL-760	DMHC5YG	Phase 1	NA	[88]
Iboctadekin	DMHS29U	Phase 1	NA	[89]
IGM-2323	DMMPINS	Phase 1	Antibody	[90]
IGN002	DME0ONY	Phase 1	NA	[2]
IM19	DM43X0Q	Phase 1	CAR T Cell Therapy	[91]
JBH492	DM7XAV1	Phase 1	Antibody drug conjugate	[92]
JCAR018	DMR3SO5	Phase 1	NA	[9]
JNJ-64264681	DMLYAGD	Phase 1	NA	[93]
JNJ-67856633	DM6URNJ	Phase 1	NA	[94]
JNJ-75348780	DMSDSFX	Phase 1	Bispecific antibody	[95]
JWCAR029	DMHMDC0	Phase 1	CAR T Cell Therapy	[96]
KPT-9274	DM9JXMD	Phase 1	NA	[2]
LAM-003	DMQHWMJ	Phase 1	NA	[2]
NAM-NK cells	DMTWKVH	Phase 1	Cell therapy	[97]
NAM-NK cells + IL-2	DMEXQNL	Phase 1	NA	[2]
NKX019	DMOQDN0	Phase 1	CAR-NK cell therapy	[98]
NX-2127	DMIE2OG	Phase 1	Small molecule	[99]
NX-5948	DM6GHMC	Phase 1	Small molecule	[100]
Oncoquest-L	DMOZ2L6	Phase 1	NA	[101]
PF-05082566	DMAEK3L	Phase 1	NA	[102]
PF-06801591	DMDE9I6	Phase 1	Antibody	[103]
PSB202	DM5RGU8	Phase 1	NA	[104]
RG6333	DM1BRF2	Phase 1	Bispecific antibody	[105]
RG7986	DM1MIZB	Phase 1	NA	[9]
RO7082859	DM4PSF9	Phase 1	NA	[2]
RO7443904	DMSWZNU	Phase 1	Bispecific antibody	[106]
RP4010	DME9UTO	Phase 1	NA	[2]
SGN-CD19B	DMGG7TT	Phase 1	NA	[2]
SGN-CD70A	DMMJ1PO	Phase 1	Antibody	[107]
Sym021	DMVXLS5	Phase 1	Monoclonal antibody	[103]
TG-1701	DMNDHKL	Phase 1	Small molecular drug	[108]
Tobacco plant-derived anti-idiotype vaccine	DMRDEFI	Phase 1	NA	[109]
TRPH-222	DMSLQW2	Phase 1	Antibody drug conjugate	[110]
VIP-152	DMBQ5OL	Phase 1	Small molecule	[111]
VOB560	DMDG30Q	Phase 1	Small molecular drug	[112]
XmAb13676	DMXTOCE	Phase 1	NA	[9]
CD19-UCART	DM8VTF2	Clinical trial	CAR T Cell Therapy	[113]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DCDT-2980S	DMGM2HY	Discontinued in Phase 2	Antibody	[114]
Dacetuzumab	DMP3X6Q	Terminated	Monoclonal antibody	[115]
Nimesulide	DMR1NMD	Terminated	Small molecular drug	[116]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anti-BCR mabs	DMJL7K7	Investigative	Monoclonal antibody	[117]
AVP-5	DM3R7JF	Investigative	NA	[117]
BLX-301	DM728RW	Investigative	Antibody	[118]
BVX-20-CD20	DMAVDNU	Investigative	Antibody	[118]
CD79-targeted immunotoxins	DMWP63C	Investigative	Antibody	[119]
CGEN-712	DMYAXJO	Investigative	NA	[117]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 109 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ATIC	TT9NVXQ	Limited	Biomarker	[122]
BTK	TTGM6VW	Limited	Biomarker	[123]
CCND3	TT1JXNR	Limited	Genetic Variation	[124]
CDC25A	TTLZS4Q	Limited	Altered Expression	[125]
CMA1	TT8VUE0	Limited	Altered Expression	[126]
CYP2C9	TTR40YJ	Limited	Genetic Variation	[127]
FGFR4	TT1KX2S	Limited	Genetic Variation	[128]
IRF8	TTHUBNK	Limited	Genetic Variation	[129]
NME1	TTDY8JH	Limited	Biomarker	[130]
NR0B2	TT25A9Q	Limited	Biomarker	[131]
PTPN6	TT369M5	Limited	Biomarker	[131]
SERPINA6	TTJL8VG	Limited	Altered Expression	[132]
SLC16A1	TTN1J82	Limited	Altered Expression	[126]
SLC23A1	TT6XAGK	Limited	Genetic Variation	[133]
SLC23A2	TTOP832	Limited	Genetic Variation	[133]
BRAF	TT0EOB8	Disputed	Biomarker	[134]
CCL21	TTLZK1U	Disputed	Genetic Variation	[135]
CXCR5	TTIW59R	Disputed	Genetic Variation	[136]
CYP2E1	TTWVHQ5	Disputed	Genetic Variation	[127]
PAX5	TTA4REJ	Disputed	Biomarker	[137]
TLR1	TTW14D0	Disputed	Genetic Variation	[138]
AICDA	TTKRTP6	moderate	Biomarker	[139]
CBS	TTVZJ7G	moderate	Genetic Variation	[140]
CCR9	TTIPS8B	moderate	Biomarker	[141]
IFNGR2	TT13TL0	moderate	Genetic Variation	[142]
IFNL3	TTRF4Q2	moderate	Biomarker	[143]
ALK	TTPMQSO	Strong	Biomarker	[144]
APOH	TT2OUI9	Strong	Biomarker	[145]
ATM	TTKBM7V	Strong	Genetic Variation	[146]
ATRAID	TTFLIKM	Strong	Biomarker	[147]
BIRC7	TTHZ8TA	Strong	Biomarker	[148]
BRD2	TTDP48B	Strong	Genetic Variation	[149]
CASP10	TTX5HEK	Strong	Genetic Variation	[150]
CD19	TTW640A	Strong	Biomarker	[151]
CD22	TTM6QSK	Strong	Biomarker	[152]
CD28	TTQ13FT	Strong	Biomarker	[153]
CD37	TTFCW29	Strong	Biomarker	[154]
CD40LG	TTIJP3Q	Strong	Biomarker	[155]
CD47	TT28S46	Strong	Biomarker	[156]
CD5	TTEGYK1	Strong	Biomarker	[157]
CD52	TTQT5S9	Strong	Biomarker	[158]
CD70	TTNCIE0	Strong	Biomarker	[159]
CD79B	TTBN5I7	Strong	Biomarker	[160]
CDK11B	TT5Q79O	Strong	Genetic Variation	[161]
CDKN2C	TTBRUGA	Strong	Biomarker	[147]
CES1	TTMF541	Strong	Genetic Variation	[162]
CR2	TT0HUN7	Strong	Altered Expression	[163]
CRY2	TTAO58M	Strong	Genetic Variation	[164]
CSF3R	TTC70AJ	Strong	Biomarker	[165]
DYRK2	TT84OS6	Strong	Biomarker	[166]
EPHX2	TT7WVHI	Strong	Genetic Variation	[162]
FAS	TT7LTUJ	Strong	Biomarker	[167]
FCGR1A	TTZK4I3	Strong	Altered Expression	[168]
FCGR2A	TTXT21W	Strong	Biomarker	[169]
FCGR2B	TT5RWKQ	Strong	Biomarker	[170]
FMNL1	TTW20PQ	Strong	Altered Expression	[171]
GBA	TT1B5PU	Strong	Biomarker	[172]
GGH	TTZJRL0	Strong	Genetic Variation	[173]
GPR132	TTNBW4F	Strong	Biomarker	[174]
GPR34	TTVXSTQ	Strong	Altered Expression	[175]
GPX1	TTYAHBP	Strong	Genetic Variation	[176]
GUCY2D	TTWNFC2	Strong	Biomarker	[177]
HLA-DRB1	TTUXSTW	Strong	Genetic Variation	[178]
IL12A	TTRTK6Y	Strong	Biomarker	[179]
IL1R2	TT51DEV	Strong	Altered Expression	[180]
KIR2DS1	TTVWAGF	Strong	Biomarker	[181]
KMT5A	TTGC95K	Strong	Genetic Variation	[182]
LAIR1	TTSI7A8	Strong	Biomarker	[183]
LANCL1	TTZW8NS	Strong	Altered Expression	[184]
LTA	TTP73TM	Strong	Genetic Variation	[185]
LTB	TTHQ6US	Strong	Altered Expression	[186]
LTK	TT1JZG6	Strong	Genetic Variation	[187]
LYVE1	TTG8DNU	Strong	Biomarker	[188]
MASP2	TTR01E9	Strong	Genetic Variation	[189]
NPM1	TTHBS98	Strong	Biomarker	[190]
NPR2	TTNB7IF	Strong	Biomarker	[172]
PMS1	TTX1ISF	Strong	Genetic Variation	[191]
PSMB6	TT8EPLT	Strong	Biomarker	[192]
PTPN13	TT405FP	Strong	Biomarker	[193]
PTPRJ	TTWMKXP	Strong	Genetic Variation	[194]
RGS6	TTJ96M8	Strong	Altered Expression	[195]
RNF34	TTEWDK1	Strong	Biomarker	[196]
RORB	TTGB2LZ	Strong	Genetic Variation	[197]
RRM1	TTWP0NS	Strong	Biomarker	[198]
RXRB	TTKLV96	Strong	Genetic Variation	[199]
S1PR2	TTVSMOH	Strong	Biomarker	[200]
SELL	TT2IYXF	Strong	Altered Expression	[201]
SERPING1	TTVQ6R9	Strong	Biomarker	[202]
SPN	TTOZAX0	Strong	Biomarker	[203]
SYK	TT2HUPM	Strong	Genetic Variation	[199]
TCL1A	TTUKRDV	Strong	Biomarker	[204]
TFRC	TT8MG4S	Strong	Biomarker	[205]
TIGIT	TTWNL74	Strong	Biomarker	[206]
TIRAP	TTKU0LS	Strong	Genetic Variation	[207]
TLR6	TTWRI8V	Strong	Genetic Variation	[138]
TNFRSF14	TTWGTC1	Strong	Biomarker	[208]
TNFRSF17	TTZ3P4W	Strong	Altered Expression	[209]
TNFRSF8	TT2GM5R	Strong	Biomarker	[144]
TNFSF13B	TTWMIDN	Strong	Biomarker	[210]
TSPAN7	TTMT6VE	Strong	Altered Expression	[211]
TYRO3	TTIEMFN	Strong	Biomarker	[212]
VIPR1	TTCL30I	Strong	Genetic Variation	[213]
WRN	TT2H5WQ	Strong	Genetic Variation	[214]
CHEK2	TT9ABMF	Definitive	Biomarker	[215]
CSF2	TTNYZG2	Definitive	Therapeutic	[216]
CSF3	TT5TQ2W	Definitive	Genetic Variation	[217]
IFNA2	TTSIUJ9	Definitive	Therapeutic	[218]
KIT	TTX41N9	Definitive	Biomarker	[219]
NR1I3	TTRANFM	Definitive	Biomarker	[220]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC35B2	DT81RKJ	Strong	Genetic Variation	[221]

This Disease Is Related to 5 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NAT10	DEZV4AP	Disputed	Genetic Variation	[222]
AKR1C1	DE7P2FB	Strong	Genetic Variation	[223]
CES2	DETHCPD	Strong	Biomarker	[224]
EPHX1	DELB4KP	Strong	Biomarker	[225]
FPGS	DECWT2V	Strong	Biomarker	[226]

This Disease Is Related to 161 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARHGAP24	OTCQCEZS	Limited	Biomarker	[227]
ASPG	OT5E2EKR	Limited	Biomarker	[228]
ASXL1	OTX931AW	Limited	Biomarker	[229]
BACH2	OT17GS18	Limited	Genetic Variation	[230]
CLEC4D	OTT7X1UC	Limited	Biomarker	[231]
CYBA	OT16N9ZO	Limited	Genetic Variation	[232]
FH	OTEQWU6Q	Limited	Biomarker	[231]
GPANK1	OT1TN2KT	Limited	Genetic Variation	[233]
MCAT	OTH07FIW	Limited	Altered Expression	[126]
MCTS1	OT7SAOJP	Limited	Altered Expression	[126]
MOS	OTNMQPFJ	Limited	Biomarker	[234]
MRPL28	OT4LUTZU	Limited	Biomarker	[235]
MTSS1	OT5DTDO2	Limited	Biomarker	[236]
MTX1	OTLSDNZO	Limited	Genetic Variation	[173]
MYOD1	OTV2S79X	Limited	Posttranslational Modification	[237]
NXT1	OT0VO6AY	Limited	Biomarker	[235]
RIT1	OTVNOGOH	Limited	Biomarker	[224]
SUB1	OTK71JYU	Limited	Biomarker	[235]
TET2	OTKKT03T	Limited	Genetic Variation	[238]
TRAF1	OTTLM5RU	Limited	Genetic Variation	[239]
ATRNL1	OTY5JUX2	Disputed	Genetic Variation	[222]
BCL3	OT1M5B95	Disputed	Altered Expression	[240]
PDLIM3	OTVXQC81	Disputed	Genetic Variation	[222]
SHMT1	OTIINA3J	Disputed	Biomarker	[140]
SMC4	OTEJE6AG	Disputed	Biomarker	[241]
CCL1	OT23NON8	moderate	Genetic Variation	[141]
CRTAP	OT53H5U6	moderate	Genetic Variation	[242]
CYTIP	OTRJ3ZC5	moderate	Genetic Variation	[242]
DYNLL1	OTR69LHT	moderate	Biomarker	[243]
EEF2	OTZ7SZ39	moderate	Altered Expression	[244]
GOLGA7	OT72NQLJ	moderate	Genetic Variation	[245]
HOXC5	OTPQTLKZ	moderate	Altered Expression	[246]
HOXC6	OTBCRAZV	moderate	Altered Expression	[246]
KRT81	OTMKIK2S	moderate	Genetic Variation	[247]
MARCKSL1	OT13J2FM	moderate	Biomarker	[248]
NCOA1	OTLIUJQD	moderate	Genetic Variation	[249]
RBM45	OTWTHD77	moderate	Genetic Variation	[178]
RYR3	OT4EHIP4	moderate	Genetic Variation	[245]
TMEM260	OTICII2L	moderate	Genetic Variation	[245]
ACAA1	OTVKRET0	Strong	Biomarker	[250]
ACSBG1	OTM040MW	Strong	Biomarker	[251]
ADAM12	OTZKOTDB	Strong	Altered Expression	[252]
ALDH1L1	OT15HOJX	Strong	Genetic Variation	[140]
ARMH1	OTTJC0D6	Strong	Altered Expression	[184]
BAG5	OT0J97C6	Strong	Genetic Variation	[253]
BCL2L11	OTNQQWFJ	Strong	Genetic Variation	[254]
BCL7A	OTYFUJTP	Strong	Genetic Variation	[255]
BCLAF1	OT7T8H6A	Strong	Genetic Variation	[253]
BCR	OTCN76C1	Strong	Biomarker	[256]
BHMT	OTYB6PXZ	Strong	Biomarker	[226]
C1RL	OTRTQWRV	Strong	Genetic Variation	[257]
C6orf47	OTMKBNDD	Strong	Genetic Variation	[233]
CALM2	OTNYA92F	Strong	Biomarker	[252]
CAMKMT	OTLJBRUW	Strong	Biomarker	[252]
CARD11	OTRCTLYC	Strong	Genetic Variation	[258]
CAV3	OTWSFDB4	Strong	Altered Expression	[259]
CCAR1	OTUXLQZZ	Strong	Biomarker	[196]
CD79A	OTOJC8DV	Strong	Altered Expression	[260]
CDC6	OTX93FE7	Strong	Biomarker	[261]
CDCA5	OTZLCQ5U	Strong	Biomarker	[184]
CFAP97	OT0RSQO4	Strong	Biomarker	[262]
CFC1	OT5DHGI8	Strong	Biomarker	[263]
DCTN6	OTI8PIN9	Strong	Altered Expression	[125]
DEFB126	OT9NHGQE	Strong	Genetic Variation	[189]
DERL2	OTI3TUUZ	Strong	Biomarker	[264]
DHX33	OTREUESJ	Strong	Altered Expression	[265]
DIXDC1	OT87DXEG	Strong	Altered Expression	[266]
DLC1	OTP8LMCR	Strong	Biomarker	[243]
DLEC1	OTMKKBUW	Strong	Posttranslational Modification	[267]
EBNA1BP2	OTBRVMZH	Strong	Altered Expression	[184]
EDIL3	OTDVVNS0	Strong	Genetic Variation	[268]
EEF1E1	OTRA6XOB	Strong	Biomarker	[147]
EIF4A2	OT08H03R	Strong	Biomarker	[269]
EIF4G1	OT2CF1E6	Strong	Biomarker	[269]
ERCC2	OT1C8HQ4	Strong	Genetic Variation	[270]
FAM72A	OTBZYSR3	Strong	Biomarker	[271]
FAM72B	OT6AOG64	Strong	Biomarker	[271]
FBLIM1	OTFHXMON	Strong	Biomarker	[272]
FCGR2C	OTNLMNYB	Strong	Biomarker	[170]
FLT3LG	OTU0YGC4	Strong	Altered Expression	[273]
GCHFR	OTEOT8GI	Strong	Biomarker	[184]
GNA15	OTFYRZGV	Strong	Altered Expression	[274]
GOPC	OTRBGH71	Strong	Biomarker	[272]
GSTM3	OTLA2WJT	Strong	Genetic Variation	[127]
H2AX	OT18UX57	Strong	Genetic Variation	[275]
HSPA1L	OTC2V1K6	Strong	Genetic Variation	[276]
HSPH1	OTVRR73T	Strong	Biomarker	[277]
ID4	OTPMJ39I	Strong	Biomarker	[278]
IL10RA	OTOX3D1D	Strong	Genetic Variation	[279]
IL12RB1	OTM1IJO2	Strong	Biomarker	[179]
IL2RG	OTRZ3OMY	Strong	Genetic Variation	[280]
INSL3	OT7KUNTE	Strong	Biomarker	[250]
ISL1	OTVNVKAX	Strong	Altered Expression	[281]
KIR2DL5A	OT09FZE1	Strong	Biomarker	[181]
KIR2DL5B	OTSV0JL9	Strong	Biomarker	[181]
KIR3DS1	OTJWIO4T	Strong	Biomarker	[181]
KRIT1	OT58AP1I	Strong	Biomarker	[252]
LAMTOR1	OTIBJBW9	Strong	Biomarker	[147]
LGALS7	OTMSVI7R	Strong	Biomarker	[282]
LIMD1	OTN1CG6R	Strong	Biomarker	[283]
LSP1	OTSPSIFO	Strong	Genetic Variation	[238]
MAFK	OTZJUE4P	Strong	Biomarker	[147]
MEF2B	OT880SE6	Strong	Genetic Variation	[284]
MIB1	OT5C404P	Strong	Biomarker	[285]
MRE11	OTGU8TZM	Strong	Genetic Variation	[146]
MSH5	OTDARQT3	Strong	Genetic Variation	[238]
MYCL	OT1MFQ5U	Strong	Genetic Variation	[286]
NCF4	OTX007YL	Strong	Genetic Variation	[287]
NCOR2	OTY917X0	Strong	Biomarker	[288]
NECTIN2	OTIE0W6O	Strong	Altered Expression	[206]
NFKBIL1	OTYFTPS0	Strong	Genetic Variation	[289]
NPAS2	OTMRT2TS	Strong	Biomarker	[290]
OCM	OTQRML29	Strong	Genetic Variation	[140]
ORC4	OT3ACTST	Strong	Genetic Variation	[291]
PCDHGB7	OTBNJN7B	Strong	Posttranslational Modification	[292]
PDE6H	OTMLRB1D	Strong	Biomarker	[177]
PER3	OTVKYVJA	Strong	Genetic Variation	[197]
PLEKHG2	OTMGR6I6	Strong	Biomarker	[228]
PLEKHO1	OTMVUQ9W	Strong	Biomarker	[293]
PLXNA2	OTNNBJMQ	Strong	Biomarker	[294]
POLD4	OTG578YH	Strong	Genetic Variation	[295]
POLE3	OTOELRF6	Strong	Biomarker	[271]
POLE4	OTCMWUT6	Strong	Genetic Variation	[295]
PRRC2A	OTBX6FM5	Strong	Genetic Variation	[254]
PSMD7	OT7PZZ4K	Strong	Altered Expression	[184]
RABEPK	OTCZSREH	Strong	Altered Expression	[184]
RAD50	OTYMU9G1	Strong	Genetic Variation	[296]
RAPH1	OTMQXW7S	Strong	Biomarker	[251]
RHOH	OT1J9SEB	Strong	Biomarker	[297]
RING1	OTCWTAX0	Strong	Genetic Variation	[199]
RNASE3	OTVE2XD1	Strong	Biomarker	[298]
RTEL1	OTI3PJCT	Strong	Biomarker	[299]
SCYL1	OTQ0IN7P	Strong	Altered Expression	[300]
SEMG1	OT6Z4BPQ	Strong	Biomarker	[301]
SHMT2	OT5NCAZN	Strong	Genetic Variation	[302]
SMARCAL1	OTTKXLUZ	Strong	Biomarker	[303]
SMUG1	OT2YIOCQ	Strong	Biomarker	[304]
STIL	OT9799VN	Strong	Biomarker	[305]
TANK	OTZSGFIK	Strong	Genetic Variation	[289]
TBC1D9	OTSSCTB5	Strong	Genetic Variation	[306]
TCL1B	OT4CSO39	Strong	Biomarker	[204]
TCN1	OTW6A49Y	Strong	Biomarker	[140]
TFDP1	OT6RZ7VT	Strong	Altered Expression	[307]
TGFBR3	OTQOOUC4	Strong	Altered Expression	[308]
TIA1	OTGPN3P8	Strong	Biomarker	[309]
TICAM2	OTK7GIJ5	Strong	Altered Expression	[125]
TJP1	OTBDCUPK	Strong	Biomarker	[310]
TLR10	OTQ1KVJO	Strong	Genetic Variation	[138]
TNFAIP8	OT1G9297	Strong	Genetic Variation	[311]
TNFSF8	OTDYGDJ3	Strong	Altered Expression	[312]
TNIP1	OTRAOTEW	Strong	Altered Expression	[313]
TOGARAM1	OTG6CYJ0	Strong	Genetic Variation	[245]
TP73	OT0LUO47	Strong	Biomarker	[314]
TPPP2	OTI3WA6X	Strong	Biomarker	[147]
TRAF3	OT5TQBGV	Strong	Altered Expression	[315]
ARR3	OTRZ00CH	Definitive	Biomarker	[220]
BCL10	OT47MCLI	Definitive	Genetic Variation	[316]
CXADR	OT9ZP02A	Definitive	Biomarker	[220]
MIXL1	OT584VOQ	Definitive	Altered Expression	[317]
SPG7	OT8OY9ST	Definitive	Biomarker	[220]
TRIM13	OTQIUACB	Definitive	Biomarker	[220]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] ClinicalTrials.gov (NCT03310619) A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216059.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 844).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6781).
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] ClinicalTrials.gov (NCT01266174) Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults. U.S. National Institutes of Health.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5693).
• [12] ClinicalTrials.gov (NCT01479244) Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence. U.S. National Institutes of Health.
• [13] Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.Eur J Cancer. 2009 Sep;45(13):2324-32.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024408)
• [15] ClinicalTrials.gov (NCT00354926) Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [17] ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
• [18] ClinicalTrials.gov (NCT02875223) A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT03930953) A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL). U.S.National Institutes of Health.
• [20] ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
• [21] Clinical pipeline report, company report or official report of Portola.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Curr Cancer Drug Targets. 2014;14(6):517-36.
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034127)
• [25] Clinical pipeline report, company report or official report of Roche.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5682).
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8273).
• [28] ClinicalTrials.gov (NCT02594384) A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) (LAM-002A/NHL). U.S. National Institutes of Health.
• [29] ClinicalTrials.gov (NCT03488251) PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
• [30] ClinicalTrials.gov (NCT02564744) Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL. U.S. National Institutes of Health.
• [31] A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20.
• [32] ClinicalTrials.gov (NCT01786135) A Safety Study of SGN-CD19A for B-Cell Lymphoma. U.S. National Institutes of Health.
• [33] Clinical pipeline report, company report or official report of Tessa Therapeutics
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8268).
• [35] ClinicalTrials.gov (NCT00818480) An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155. U.S. National Institutes of Health.
• [36] ClinicalTrials.gov (NCT00001575) Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia. U.S. National Institutes of Health.
• [37] ClinicalTrials.gov (NCT03925935) Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation. U.S. National Institutes of Health.
• [38] ClinicalTrials.gov (NCT04775680) Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma. U.S. National Institutes of Health.
• [39] ClinicalTrials.gov (NCT01994382) A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL). U.S.National Institutes of Health.
• [40] ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
• [41] ClinicalTrials.gov (NCT01796171) A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [42] ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
• [43] ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
• [44] ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
• [45] ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
• [46] ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
• [47] ClinicalTrials.gov (NCT04035434) A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON). U.S. National Institutes of Health.
• [48] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015033)
• [49] ClinicalTrials.gov (NCT04419389) APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R). U.S. National Institutes of Health.
• [50] ClinicalTrials.gov (NCT03598608) A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies. U.S.National Institutes of Health.
• [51] ClinicalTrials.gov (NCT05296525) A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma. U.S.National Institutes of Health.
• [52] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041075)
• [53] ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
• [54] ClinicalTrials.gov (NCT03664635) MB-CART20.1 Lymphoma
• [55] ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
• [56] ClinicalTrials.gov (NCT04030195) Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL. U.S. National Institutes of Health.
• [57] ClinicalTrials.gov (NCT04323657) TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia. U.S. National Institutes of Health.
• [58] ClinicalTrials.gov (NCT03590574) Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma
• [59] ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
• [60] ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
• [61] ClinicalTrials.gov (NCT02106091) Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL or B-precursor ALL. U.S. National Institutes of Health.
• [62] Clinical pipeline report, company report or official report of Allogene Therapeutics.
• [63] ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
• [64] ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
• [65] ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
• [66] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033790)
• [67] ClinicalTrials.gov (NCT04872166) A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [68] ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
• [69] ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
• [70] ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
• [71] ClinicalTrials.gov (NCT01353625) Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT04089527) Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [73] ClinicalTrials.gov (NCT04231747 ) A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [74] ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
• [75] ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
• [76] ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
• [77] ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy
• [78] ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
• [79] ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
• [80] CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
• [81] ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
• [82] ClinicalTrials.gov (NCT03690011) Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
• [83] ClinicalTrials.gov (NCT04502706) Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [84] ClinicalTrials.gov (NCT01356173) Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma. U.S. National Institutes ofHealth.
• [85] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5684).
• [86] ClinicalTrials.gov (NCT04390737) Evaluate the Safety and Clinical Activity of HH2853. U.S. National Institutes of Health.
• [87] ClinicalTrials.gov (NCT03779113) An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma. U.S. National Institutes of Health.
• [88] ClinicalTrials.gov (NCT05176691) A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL). U.S.National Institutes of Health.
• [89] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008435)
• [90] ClinicalTrials.gov (NCT04082936) A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [91] ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
• [92] ClinicalTrials.gov (NCT04240704) Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.
• [93] ClinicalTrials.gov (NCT04210219) A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT03900598) A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
• [95] ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health.
• [96] ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
• [97] ClinicalTrials.gov (NCT03019666) Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL. U.S. National Institutes of Health.
• [98] ClinicalTrials.gov (NCT05020678) A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies. U.S.National Institutes of Health.
• [99] ClinicalTrials.gov (NCT04830137) A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies. U.S.National Institutes of Health.
• [100] ClinicalTrials.gov (NCT05131022) A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies. U.S.National Institutes of Health.
• [101] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [102] ClinicalTrials.gov (NCT02179918) A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036). U.S. National Institutes of Health.
• [103] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [104] ClinicalTrials.gov (NCT05003141) A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies. U.S.National Institutes of Health.
• [105] Clinical pipeline report, company report or official report of Roche
• [106] ClinicalTrials.gov (NCT05219513) An Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. U.S.National Institutes of Health.
• [107] ClinicalTrials.gov (NCT02216890) Safety Study of SGN-CD70A in Cancer Patients. U.S. National Institutes of Health.
• [108] ClinicalTrials.gov (NCT03671590) Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies. U.S. National Institutes of Health.
• [109] Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma. Biomed Res Int. 2015;2015:648143.
• [110] ClinicalTrials.gov (NCT03682796) Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
• [111] ClinicalTrials.gov (NCT04978779) An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter Syndrome. U.S.National Institutes of Health.
• [112] ClinicalTrials.gov (NCT04702425) VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma). U.S. National Institutes of Health.
• [113] ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART
• [114] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027651)
• [115] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [116] Clinical pipeline report, company report or official report of Genentech (2011).
• [117] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [118] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [119] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852).
• [120] ClinicalTrials.gov (NCT00486759) A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health.
• [121] J Clin Oncol 27:15s, 2009 (suppl, abstr 8566).
• [122] Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.Blood. 2000 Mar 15;95(6):2144-9.
• [123] The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.Mol Carcinog. 2019 Jun;58(6):944-956. doi: 10.1002/mc.22983. Epub 2019 Feb 27.
• [124] Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Mnster protocols.Haematologica. 2017 Jun;102(6):1091-1098. doi: 10.3324/haematol.2016.156885. Epub 2017 Feb 16.
• [125] Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.Diagn Mol Pathol. 2003 Sep;12(3):128-32. doi: 10.1097/00019606-200309000-00003.
• [126] Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.Cell Oncol (Dordr). 2019 Jun;42(3):303-318. doi: 10.1007/s13402-019-00426-2. Epub 2019 Feb 21.
• [127] Genetic variations in xenobiotic metabolic pathway genes, personal hair dye use, and risk of non-Hodgkin lymphoma.Am J Epidemiol. 2009 Nov 15;170(10):1222-30. doi: 10.1093/aje/kwp263. Epub 2009 Oct 12.
• [128] Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.Tumour Biol. 2014 Apr;35(4):2997-3002. doi: 10.1007/s13277-013-1386-7. Epub 2013 Nov 19.
• [129] Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes.Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):461-6. doi: 10.1158/1055-9965.EPI-12-1217. Epub 2013 Jan 10.
• [130] Serum nm23-H1 protein as a prognostic factor in hematological malignancies.Leuk Lymphoma. 2002 Apr;43(4):859-67. doi: 10.1080/10428190290017006.
• [131] Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.Cancer Gene Ther. 2019 Jul;26(7-8):195-207. doi: 10.1038/s41417-018-0057-7. Epub 2018 Nov 23.
• [132] Association of aberrant transcortin levels with HLA antigens of the B and C loci: high transcortin levels are frequently found in patients with lymphatic leukemia, hairy cell leukemia, or non-Hodgkin lymphoma.J Clin Endocrinol Metab. 1980 Oct;51(4):868-72. doi: 10.1210/jcem-51-4-868.
• [133] Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.PLoS One. 2008 Jun 30;3(7):e2816. doi: 10.1371/journal.pone.0002816.
• [134] Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.Methods Mol Biol. 2017;1541:279-293. doi: 10.1007/978-1-4939-6703-2_22.
• [135] Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach.Radiol Oncol. 2017 Sep 18;51(4):455-462. doi: 10.1515/raon-2017-0040. eCollection 2017 Dec.
• [136] CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.Cancer Immunol Immunother. 2013 Sep;62(9):1475-84. doi: 10.1007/s00262-013-1452-4. Epub 2013 Jun 28.
• [137] Level of PAX5 in differential diagnosis of non-Hodgkin's lymphoma.Indian J Med Res. 2016 May;143(Supplement):S23-S31. doi: 10.4103/0971-5916.191747.
• [138] A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma.Carcinogenesis. 2009 Feb;30(2):275-81. doi: 10.1093/carcin/bgn262. Epub 2008 Nov 24.
• [139] Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.J Hematol Oncol. 2019 Jul 5;12(1):70. doi: 10.1186/s13045-019-0767-9.
• [140] Genetic polymorphisms in the one-carbon metabolism pathway genes and susceptibility to non-Hodgkin lymphoma.Tumour Biol. 2015 Mar;36(3):1819-34. doi: 10.1007/s13277-014-2785-0. Epub 2014 Nov 11.
• [141] Single-nucleotide polymorphisms in genes encoding for CC chemokines were not associated with the risk of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1332-5. doi: 10.1158/1055-9965.EPI-13-0328. Epub 2013 May 2.
• [142] Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Blood. 2011 Jan 13;117(2):585-90. doi: 10.1182/blood-2010-07-295097. Epub 2010 Oct 15.
• [143] Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma.Front Microbiol. 2019 Mar 15;10:475. doi: 10.3389/fmicb.2019.00475. eCollection 2019.
• [144] A first time report on the coocurrence of sarcoidosis and ALK(-) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment.J Oncol Pharm Pract. 2019 Oct;25(7):1801-1805. doi: 10.1177/1078155219837331. Epub 2019 Mar 25.
• [145] Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma.Eur J Haematol. 2002 Feb;68(2):84-90. doi: 10.1034/j.1600-0609.2002.01526.x.
• [146] Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.PLoS One. 2014 Jul 10;9(7):e101685. doi: 10.1371/journal.pone.0101685. eCollection 2014.
• [147] Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.Blood. 1995 Oct 15;86(8):2900-5.
• [148] Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma.Leuk Lymphoma. 2006 Jun;47(6):1110-6. doi: 10.1080/10428190500472271.
• [149] Genetic polymorphisms in cytochrome P450s, GSTs, NATs, alcohol consumption and risk of non-Hodgkin lymphoma.Am J Hematol. 2010 Mar;85(3):213-5. doi: 10.1002/ajh.21608.
• [150] SUMO-Modified FADD Recruits Cytosolic Drp1 and Caspase-10 to Mitochondria for Regulated Necrosis.Mol Cell Biol. 2017 Jan 4;37(2):e00254-16. doi: 10.1128/MCB.00254-16. Print 2017 Jan 15.
• [151] Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
• [152] CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models.Mol Cancer Ther. 2018 Jan;17(1):161-168. doi: 10.1158/1535-7163.MCT-17-0776. Epub 2017 Nov 15.
• [153] PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.Front Immunol. 2018 Aug 30;9:1955. doi: 10.3389/fimmu.2018.01955. eCollection 2018.
• [154] Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241. doi: 10.1007/s00259-018-3964-9. Epub 2018 Feb 22.
• [155] Emerging therapeutic options for Waldenstrm macroglobulinemia/lymphoplasmacytic lymphoma.Expert Rev Anticancer Ther. 2015;15(10):1143-56. doi: 10.1586/14737140.2015.1071668. Epub 2015 Jul 21.
• [156] Anti-CD47 Agent Boosts Macrophage Activity in NHL.Cancer Discov. 2019 Jan;9(1):7-8. doi: 10.1158/2159-8290.CD-NB2018-155. Epub 2018 Nov 21.
• [157] Histogenesis of diffuse small cleaved cell lymphoma. An immunohistochemical and molecular genetic (bcl-2 gene) study with comparison to follicular small cleaved cell lymphoma and mantle zone lymphoma.Cancer. 1992 Aug 15;70(4):821-9. doi: 10.1002/1097-0142(19920815)70:4<821::aid-cncr2820700417>3.0.co;2-y.
• [158] Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.Exp Hematol. 1996 Jul;24(8):919-26.
• [159] A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.Invest New Drugs. 2019 Apr;37(2):297-306. doi: 10.1007/s10637-018-0655-0. Epub 2018 Aug 22.
• [160] Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.Br J Pharmacol. 2017 Apr;174(8):628-640. doi: 10.1111/bph.13697. Epub 2017 Mar 6.
• [161] Deletion of cell division cycle 2-like 1 gene locus on 1p36 in non-Hodgkin lymphoma.Cancer Genet Cytogenet. 1999 Jan 15;108(2):120-6. doi: 10.1016/s0165-4608(98)00138-1.
• [162] The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma.J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9. doi: 10.1097/QAI.0b013e3181b017d5.
• [163] Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO.Blood. 1996 Feb 1;87(3):1045-55.
• [164] Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.Cancer Res. 2009 Apr 15;69(8):3605-13. doi: 10.1158/0008-5472.CAN-08-4572. Epub 2009 Mar 24.
• [165] G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells.Cytokine. 2019 Apr;116:38-47. doi: 10.1016/j.cyto.2018.12.011. Epub 2019 Jan 24.
• [166] Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.Int J Biol Macromol. 2015 Nov;81:809-17. doi: 10.1016/j.ijbiomac.2015.08.067. Epub 2015 Sep 2.
• [167] Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.Ann Hematol. 2010 Sep;89(9):889-96. doi: 10.1007/s00277-010-0945-x. Epub 2010 Mar 30.
• [168] CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.Int J Hematol. 2004 Jan;79(1):55-62. doi: 10.1007/BF02983535.
• [169] A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk.Br J Haematol. 2011 Mar;152(6):721-6. doi: 10.1111/j.1365-2141.2010.08518.x. Epub 2011 Jan 20.
• [170] Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells.Blood. 1998 Nov 1;92(9):3381-7.
• [171] High expression of FMNL1 protein in T non-Hodgkin's lymphomas.Leuk Res. 2006 Jun;30(6):735-8. doi: 10.1016/j.leukres.2005.10.003. Epub 2006 Feb 21.
• [172] Primary pancreatic diffuse large B-cell lymphoma diagnosed by endoscopic ultrasound guided FNAC: A rare entity.Diagn Cytopathol. 2020 Jan;48(1):57-60. doi: 10.1002/dc.24307. Epub 2019 Aug 24.
• [173] SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma.Pharmacogenomics. 2017 Nov;18(17):1557-1562. doi: 10.2217/pgs-2017-0110. Epub 2017 Nov 2.
• [174] Post-irradiation DNA synthesis inhibition and G2 phase delay in radiosensitive body cells from non-Hodgkin's lymphoma patients: an indication of cell cycle defects.Mutat Res. 1994 Dec 1;311(2):265-76. doi: 10.1016/0027-5107(94)90185-6.
• [175] t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.Blood. 2012 Nov 8;120(19):3949-57. doi: 10.1182/blood-2011-11-389908. Epub 2012 Sep 10.
• [176] The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin's lymphoma risk in Egypt.Infect Genet Evol. 2012 Aug;12(6):1189-94. doi: 10.1016/j.meegid.2012.04.007. Epub 2012 Apr 12.
• [177] 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma.Blood. 1993 Oct 1;82(7):2157-62.
• [178] The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients.Gene. 2016 Jul 25;586(2):263-7. doi: 10.1016/j.gene.2016.04.017. Epub 2016 Apr 7.
• [179] Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies.Br J Haematol. 2011 May;153(3):341-50. doi: 10.1111/j.1365-2141.2010.08424.x. Epub 2011 Mar 21.
• [180] Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders.Oncol Rep. 2006 May;15(5):1305-8.
• [181] Natural killer cell killer immunoglobulin-like gene receptor polymorphisms in non-Hodgkin lymphoma: possible association with clinical course.Leuk Lymphoma. 2015;56(10):2902-7. doi: 10.3109/10428194.2015.1014361. Epub 2015 Mar 27.
• [182] Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma.Tumori. 2014 Sep-Oct;100(5):553-8. doi: 10.1700/1660.18180.
• [183] Epstein-Barr virus-positive Hodgkin/Reed-Sternberg-like B cell in non-hodgkin lymphoma: nucleotide sequence of the amplified immunoglobulin heavy-chain variable region gene by the single-cell polymerase chain reaction technique.Diagn Mol Pathol. 2002 Jun;11(2):83-9. doi: 10.1097/00019606-200206000-00004.
• [184] Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL).Leuk Lymphoma. 2002 Jun;43(6):1313-21. doi: 10.1080/10428190290026385.
• [185] The +252A/G polymorphism in the Lymphotoxin- gene and the risk of non-Hodgkin lymphoma: a meta-analysis.Eur Rev Med Pharmacol Sci. 2014;18(4):544-52.
• [186] Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas.Cancer Immunol Immunother. 2000 Nov;49(9):469-75. doi: 10.1007/s002620000127.
• [187] ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK).Oncogene. 1997 May 8;14(18):2175-88. doi: 10.1038/sj.onc.1201062.
• [188] Sarcoma of follicular dendritic cells with features of sinus lining cells--a new subtype of reticulum cell sarcoma?.Virchows Arch. 2008 May;452(5):565-70. doi: 10.1007/s00428-008-0603-z.
• [189] Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.Environ Mol Mutagen. 2013 Jan;54(1):72-7. doi: 10.1002/em.21739. Epub 2012 Oct 11.
• [190] Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.Med Res Rev. 2008 May;28(3):372-412. doi: 10.1002/med.20109.
• [191] Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer.Leuk Lymphoma. 2002 Aug;43(8):1619-26. doi: 10.1080/1042819021000002956.
• [192] Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.Am J Hematol. 1996 Jul;52(3):171-7. doi: 10.1002/(SICI)1096-8652(199607)52:3<171::AID-AJH6>3.0.CO;2-Q.
• [193] 5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.Int J Mol Med. 2015 Sep;36(3):698-704. doi: 10.3892/ijmm.2015.2269. Epub 2015 Jul 1.
• [194] High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to Non-Hodgkin's lymphoma.Genes Chromosomes Cancer. 2013 May;52(5):467-79. doi: 10.1002/gcc.22044. Epub 2013 Jan 23.
• [195] Expression of the novel all-trans retinoic acid-related resistance gene HA117 in pediatric solid tumors.J Pediatr Hematol Oncol. 2014 Jan;36(1):45-50. doi: 10.1097/MPH.0b013e31828e5d73.
• [196] Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.Cancer Chemother Pharmacol. 2011 Jun;67(6):1401-13. doi: 10.1007/s00280-010-1442-6. Epub 2010 Aug 31.
• [197] Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis.Oncotarget. 2017 Apr 4;8(14):23978-23995. doi: 10.18632/oncotarget.15074.
• [198] Comparison of the expression of human equilibrative nucleotide transporter 1 (hENT1) and ribonucleotide reductase subunit M1 (RRM1) genes in seven non-Hodgkin lymphoma cell lines.Genet Mol Res. 2016 May 6;15(2). doi: 10.4238/gmr.15028275.
• [199] Variations in chromosomes 9 and 6p21.3 with risk of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):42-9. doi: 10.1158/1055-9965.EPI-10-0638. Epub 2010 Dec 10.
• [200] Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.Cancer Res. 2009 Nov 15;69(22):8686-92. doi: 10.1158/0008-5472.CAN-09-1110. Epub 2009 Nov 10.
• [201] Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L.Leuk Lymphoma. 2006 Apr;47(4):613-22. doi: 10.1080/10428190500360971.
• [202] Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.Orphanet J Rare Dis. 2019 Mar 13;14(1):65. doi: 10.1186/s13023-019-1043-3.
• [203] Analysis of clinical characteristics of 516 patients with non-Hodgkin's lymphoma in Shanghai area.Hematology. 2014 Mar;19(2):99-106. doi: 10.1179/1607845413Y.0000000097. Epub 2013 Nov 25.
• [204] EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.J Virol. 2007 Mar;81(5):2274-82. doi: 10.1128/JVI.01822-06. Epub 2006 Dec 6.
• [205] The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.Clin Immunol. 2006 Nov;121(2):144-58. doi: 10.1016/j.clim.2006.06.010. Epub 2006 Aug 10.
• [206] TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.
• [207] HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.Oncoimmunology. 2016 Dec 23;6(3):e1219825. doi: 10.1080/2162402X.2016.1219825. eCollection 2017.
• [208] Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.Leukemia. 2003 Dec;17(12):2500-7. doi: 10.1038/sj.leu.2403175.
• [209] Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.Blood. 2004 Oct 15;104(8):2247-53. doi: 10.1182/blood-2004-02-0762. Epub 2004 Jul 13.
• [210] The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors.Adv Clin Exp Med. 2016 Sep-Oct;25(5):837-844. doi: 10.17219/acem/29182.
• [211] The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
• [212] Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16541-16550. doi: 10.1073/pnas.1903991116. Epub 2019 Jul 25.
• [213] Rare HVR1-HCV genotype 1b variants in patients with B non Hodgkin's lymphoma. Comparison with viral sequences detected in cases of lymphoproliferative disorders and B cell compartmentalisation.New Microbiol. 2007 Jul;30(3):265-70.
• [214] Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Am J Hematol. 2013 Jul;88(7):606-11. doi: 10.1002/ajh.23463. Epub 2013 May 30.
• [215] Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.PLoS One. 2015 Oct 27;10(10):e0140819. doi: 10.1371/journal.pone.0140819. eCollection 2015.
• [216] DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).Eur J Haematol Suppl. 2001 Jul;64:41-5.
• [217] Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.J Med Econ. 2020 Jan;23(1):28-36. doi: 10.1080/13696998.2019.1658591. Epub 2019 Sep 3.
• [218] Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.Ann Oncol. 1994;5 Suppl 2:73-7. doi: 10.1093/annonc/5.suppl_2.s73.
• [219] IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin's lymphoma.J Clin Immunol. 2011 Dec;31(6):1084-94. doi: 10.1007/s10875-011-9584-9. Epub 2011 Sep 4.
• [220] Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
• [221] Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes.Hum Mol Genet. 2016 Apr 15;25(8):1663-76. doi: 10.1093/hmg/ddw027. Epub 2016 Feb 9.
• [222] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).Cancer Genet Cytogenet. 2010 Oct 1;202(1):38-42. doi: 10.1016/j.cancergencyto.2010.06.004.
• [223] Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma.Hum Genet. 2007 Apr;121(2):161-8. doi: 10.1007/s00439-006-0288-9. Epub 2006 Dec 6.
• [224] Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16.
• [225] Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas.Hum Mol Genet. 2001 Jun 1;10(12):1265-73. doi: 10.1093/hmg/10.12.1265.
• [226] Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study.Blood. 2007 Apr 1;109(7):3050-9. doi: 10.1182/blood-2006-07-034330.
• [227] The association between non-Hodgkin lymphoma and methylation of p73.Tumour Biol. 2011 Dec;32(6):1133-8. doi: 10.1007/s13277-011-0215-0. Epub 2011 Aug 3.
• [228] Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.
• [229] Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.Bone Marrow Transplant. 2000 Aug;26(3):321-6. doi: 10.1038/sj.bmt.1702510.
• [230] High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.Leuk Res. 2009 May;33(5):731-4. doi: 10.1016/j.leukres.2008.09.007. Epub 2008 Oct 16.
• [231] Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?.Leuk Lymphoma. 2009 Aug;50(8):1249-56. doi: 10.1080/10428190903040030.
• [232] A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.Cancer Res. 2010 Mar 15;70(6):2328-38. doi: 10.1158/0008-5472.CAN-09-2388. Epub 2010 Mar 9.
• [233] Interactions within the MHC contribute to the genetic architecture of celiac disease.PLoS One. 2017 Mar 10;12(3):e0172826. doi: 10.1371/journal.pone.0172826. eCollection 2017.
• [234] Expression of common fragile sites in untreated non-Hodgkin's lymphoma with aphidicolin and folate deficiency.Cancer Lett. 1994 Oct 28;86(1):111-7. doi: 10.1016/0304-3835(94)90187-2.
• [235] Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.J Invest Dermatol. 2002 Mar;118(3):493-9. doi: 10.1046/j.0022-202x.2001.01682.x.
• [236] Mice deficient in MIM expression are predisposed to lymphomagenesis.Oncogene. 2012 Jul 26;31(30):3561-8. doi: 10.1038/onc.2011.509. Epub 2011 Nov 14.
• [237] The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders.Leukemia. 2001 Apr;15(4):583-9. doi: 10.1038/sj.leu.2402080.
• [238] Pleiotropy of cancer susceptibility variants on the risk of non-Hodgkin lymphoma: the PAGE consortium.PLoS One. 2014 Mar 5;9(3):e89791. doi: 10.1371/journal.pone.0089791. eCollection 2014.
• [239] TRAF1 Signaling in Human Health and Disease.Front Immunol. 2018 Dec 18;9:2969. doi: 10.3389/fimmu.2018.02969. eCollection 2018.
• [240] Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas.Blood. 2005 Dec 15;106(13):4287-93. doi: 10.1182/blood-2004-09-3620. Epub 2005 Aug 25.
• [241] Condensin mutations and abnormal chromosomal structures in pyothorax-associated lymphoma.Cancer Sci. 2007 Jul;98(7):1041-7. doi: 10.1111/j.1349-7006.2007.00500.x. Epub 2007 May 4.
• [242] Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma.Carcinogenesis. 2007 Apr;28(4):823-7. doi: 10.1093/carcin/bgl196. Epub 2006 Oct 27.
• [243] DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.Mol Biol Rep. 2011 Mar;38(3):1915-20. doi: 10.1007/s11033-010-0311-z. Epub 2010 Oct 1.
• [244] The translation elongation factor eEF2 is a novel tumorassociated antigen overexpressed in various types of cancers.Int J Oncol. 2014 May;44(5):1461-9. doi: 10.3892/ijo.2014.2318. Epub 2014 Mar 4.
• [245] A polymorphism at the microRNA binding site in the 3' untranslated region of C14orf101 is associated with non-Hodgkin lymphoma overall survival.Cancer Genet. 2014 Apr;207(4):141-6. doi: 10.1016/j.cancergen.2014.03.007. Epub 2014 Mar 22.
• [246] HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin's lymphoma: preferential expression of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract mucosa-associated B-cell lymphomas.Blood. 1997 Nov 15;90(10):4116-25.
• [247] A miR-SNP of the KRT81 gene is associated with the prognosis of non-Hodgkin's lymphoma.Gene. 2014 Apr 15;539(2):198-202. doi: 10.1016/j.gene.2014.02.010. Epub 2014 Feb 12.
• [248] MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders.Br J Haematol. 1998 Aug;102(3):710-7. doi: 10.1046/j.1365-2141.1998.00822.x.
• [249] NCOA1 is a novel susceptibility gene for multiple myeloma in the Chinese population: A case-control study.PLoS One. 2017 Mar 6;12(3):e0173298. doi: 10.1371/journal.pone.0173298. eCollection 2017.
• [250] Innate immunity and non-Hodgkin's lymphoma (NHL) related genes in a nested case-control study for gastric cancer risk.PLoS One. 2012;7(9):e45274. doi: 10.1371/journal.pone.0045274. Epub 2012 Sep 21.
• [251] BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.Blood. 1998 Oct 1;92(7):2294-302.
• [252] Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.Hematology. 2017 Oct;22(9):527-535. doi: 10.1080/10245332.2017.1312205. Epub 2017 Apr 10.
• [253] Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma.Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2847-58. doi: 10.1158/1055-9965.EPI-10-0581. Epub 2010 Sep 20.
• [254] PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium.Blood. 2012 Nov 29;120(23):4645-8. doi: 10.1182/blood-2012-05-427989. Epub 2012 Oct 9.
• [255] Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1259-70. doi: 10.1158/1055-9965.EPI-08-1037. Epub 2009 Mar 31.
• [256] Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection.J Antimicrob Chemother. 2018 Nov 1;73(11):3162-3169. doi: 10.1093/jac/dky311.
• [257] Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma.Environ Mol Mutagen. 2012 Mar;53(2):145-51. doi: 10.1002/em.21675. Epub 2011 Dec 15.
• [258] Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease.Front Immunol. 2018 Sep 19;9:2105. doi: 10.3389/fimmu.2018.02105. eCollection 2018.
• [259] Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis.Cancer Res. 2000 Jun 1;60(11):2775-9.
• [260] Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.Blood. 2007 Jul 15;110(2):616-23. doi: 10.1182/blood-2007-01-066704. Epub 2007 Mar 20.
• [261] Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Mutat Res. 2009 Mar 9;662(1-2):10-5. doi: 10.1016/j.mrfmmm.2008.11.014. Epub 2008 Dec 3.
• [262] Identification of B-cell growth factors (interleukin-14; high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas.Blood. 1995 Jul 1;86(1):283-93.
• [263] Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus.Nature. 1984 Jan 26-Feb 1;307(5949):334-40. doi: 10.1038/307334a0.
• [264] Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient with CD56+ non-Hodgkin's lymphoma.Leukemia. 2001 Oct;15(10):1641-9. doi: 10.1038/sj.leu.2402239.
• [265] Role of DHX33 in c-Myc-induced cancers.Carcinogenesis. 2017 Jun 1;38(6):649-660. doi: 10.1093/carcin/bgx041.
• [266] DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas.Leuk Res. 2016 Nov;50:104-111. doi: 10.1016/j.leukres.2016.09.011. Epub 2016 Sep 8.
• [267] Epigenetic silencing of the tumor suppressor genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in childhood and adolescent lymphomas.Pediatr Hematol Oncol. 2018 Mar;35(2):131-144. doi: 10.1080/08880018.2018.1467986. Epub 2018 Jul 18.
• [268] Detection of 14q32 translocations in B-cell malignancies by in situ hybridization with yeast artificial chromosome clones containing the human IgH gene locus.Blood. 1994 May 15;83(10):2962-9.
• [269] Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.Oncotarget. 2015 Apr 20;6(11):9488-501. doi: 10.18632/oncotarget.3378.
• [270] Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.Oncotarget. 2017 Jul 18;8(29):48488-48506. doi: 10.18632/oncotarget.17290.
• [271] In-depth analysis of compartmentalization of HIV-1 matrix protein p17 in PBMC and plasma.New Microbiol. 2017 Jan;40(1):58-61. Epub 2017 Jan 9.
• [272] Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.Anticancer Res. 2015 May;35(5):2699-708.
• [273] Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma.Oncol Rep. 2002 May-Jun;9(3):525-7.
• [274] G protein subunit G alpha 16 expression is restricted to progenitor B cells during human B-cell differentiation.Blood. 1995 Apr 1;85(7):1836-42.
• [275] Sex- and subtype-specific analysis of H2AFX polymorphisms in non-Hodgkin lymphoma.PLoS One. 2013 Sep 17;8(9):e74619. doi: 10.1371/journal.pone.0074619. eCollection 2013.
• [276] Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors.Cancer. 1997 Oct 15;80(8):1489-96. doi: 10.1002/(sici)1097-0142(19971015)80:8<1489::aid-cncr17>3.0.co;2-1.
• [277] Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.
• [278] Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.Mol Med Rep. 2016 Feb;13(2):1269-74. doi: 10.3892/mmr.2015.4640. Epub 2015 Dec 4.
• [279] Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma.Am J Hematol. 2012 Aug;87(8):766-9. doi: 10.1002/ajh.23244. Epub 2012 May 31.
• [280] Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer.J Immunother. 2002 Jan-Feb;25(1):36-45. doi: 10.1097/00002371-200201000-00004.
• [281] ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.Mol Cancer. 2014 Jul 29;13:181. doi: 10.1186/1476-4598-13-181.
• [282] Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model.Cancer Res. 2007 Mar 15;67(6):2824-9. doi: 10.1158/0008-5472.CAN-06-3891.
• [283] Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma.Oncol Lett. 2019 Mar;17(3):2993-3000. doi: 10.3892/ol.2019.9921. Epub 2019 Jan 11.
• [284] The Cancer Mutation D83V Induces an -Helix to -Strand Conformation Switch in MEF2B.J Mol Biol. 2018 Apr 13;430(8):1157-1172. doi: 10.1016/j.jmb.2018.02.012. Epub 2018 Feb 22.
• [285] -tubulin nuclear overexpression is an indicator of poor prognosis in patients with non-Hodgkin's lymphoma.Int J Mol Med. 2014 Aug;34(2):483-90. doi: 10.3892/ijmm.2014.1793. Epub 2014 Jun 4.
• [286] Restriction fragment length polymorphism of the L-myc oncogene in non-Hodgkin's lymphoma patients from India.Cancer Lett. 1998 Mar 13;125(1-2):165-9. doi: 10.1016/s0304-3835(97)00509-0.
• [287] Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.Am J Hematol. 2014 Jun;89(6):639-45. doi: 10.1002/ajh.23709. Epub 2014 Apr 12.
• [288] Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.Cancer Res. 2005 Jun 1;65(11):4554-61. doi: 10.1158/0008-5472.CAN-04-4108.
• [289] Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk.PLoS One. 2009;4(4):e5360. doi: 10.1371/journal.pone.0005360. Epub 2009 Apr 24.
• [290] Silencing NPAS2 promotes cell growth and invasion in DLD-1 cells and correlated with poor prognosis of colorectal cancer.Biochem Biophys Res Commun. 2014 Jul 25;450(2):1058-62. doi: 10.1016/j.bbrc.2014.06.104. Epub 2014 Jun 27.
• [291] Novel ORC4L gene mutation in B-cell lymphoproliferative disorders.Am J Med Sci. 2009 Dec;338(6):527-9. doi: 10.1097/MAJ.0b013e3181b7f17c.
• [292] Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.Carcinogenesis. 2007 Jan;28(1):60-70. doi: 10.1093/carcin/bgl092. Epub 2006 Jun 14.
• [293] Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.Oncol Rep. 2017 Jan;37(1):622-630. doi: 10.3892/or.2016.5233. Epub 2016 Nov 8.
• [294] The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy.J Clin Pathol. 1998 Oct;51(10):776-80. doi: 10.1136/jcp.51.10.776.
• [295] Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas.Blood. 2002 Jun 1;99(11):4094-9. doi: 10.1182/blood.v99.11.4094.
• [296] Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma.BMC Med Genet. 2009 Nov 16;10:117. doi: 10.1186/1471-2350-10-117.
• [297] Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma.Oncogene. 2000 Apr 13;19(16):2023-32. doi: 10.1038/sj.onc.1203521.
• [298] Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.Cancer Res. 2005 Jan 1;65(1):264-76.
• [299] miRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon-free antiviral therapy.Antivir Ther. 2019;24(6):437-442. doi: 10.3851/IMP3322.
• [300] Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas.Leukemia. 1994 Jan;8(1):97-101.
• [301] Retrospective identification of a previously undetected clinical case of OXA-48-producing K. pneumoniae and E. coli: the importance of adequate detection guidelines.Infection. 2016 Feb;44(1):107-10. doi: 10.1007/s15010-015-0805-7. Epub 2015 Jun 11.
• [302] Polymorphisms in folate-metabolizing genes and risk of non-Hodgkin's lymphoma.Leuk Res. 2011 Apr;35(4):508-15. doi: 10.1016/j.leukres.2010.10.004. Epub 2010 Nov 4.
• [303] SMARCAL1 deficiency predisposes to non-Hodgkin lymphoma and hypersensitivity to genotoxic agents in vivo.Am J Med Genet A. 2012 Sep;158A(9):2204-13. doi: 10.1002/ajmg.a.35532. Epub 2012 Aug 7.
• [304] Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.Biol Blood Marrow Transplant. 2019 Jun;25(6):1092-1098. doi: 10.1016/j.bbmt.2019.02.008. Epub 2019 Feb 12.
• [305] Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies.Br J Haematol. 1995 Dec;91(4):871-7. doi: 10.1111/j.1365-2141.1995.tb05403.x.
• [306] Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma.Int J Mol Sci. 2014 Apr 21;15(4):6703-16. doi: 10.3390/ijms15046703.
• [307] Immunohistochemical expression of the transcription factor DP-1 and its heterodimeric partner E2F-1 in non-Hodgkin lymphoma.Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):322-6. doi: 10.1097/00129039-200212000-00006.
• [308] Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas.Med Sci Monit. 2004 Jan;10(1):CR33-7.
• [309] Paediatric T-cell lymphoma of the appendix: a case report.Diagn Pathol. 2013 Jan 9;8:2. doi: 10.1186/1746-1596-8-2.
• [310] Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients.Oncol Rep. 2013 Jul;30(1):455-61. doi: 10.3892/or.2013.2450. Epub 2013 May 10.
• [311] Lymphotoxin alpha (LTA) polymorphism is associated with prognosis of non-Hodgkin's lymphoma in a Chinese population.PLoS One. 2013 Jun 20;8(6):e66411. doi: 10.1371/journal.pone.0066411. Print 2013.
• [312] Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.Leukemia. 1994 Dec;8(12):2083-94.
• [313] Leukocyte Ig-Like receptor B1 restrains dendritic cell function through increased expression of the NF-B regulator ABIN1/TNIP1.J Leukoc Biol. 2016 Oct;100(4):737-746. doi: 10.1189/jlb.1A0915-420RRR. Epub 2016 Apr 29.
• [314] TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.Curr Mol Med. 2014 May;14(4):432-9. doi: 10.2174/1566524014666140414204458.
• [315] N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.BMC Cancer. 2013 Oct 16;13:481. doi: 10.1186/1471-2407-13-481.
• [316] Mutation of bcl-x gene in non-Hodgkin's lymphoma.Am J Hematol. 2002 Jan;69(1):74-6. doi: 10.1002/ajh.10030.
• [317] Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.Hum Pathol. 2007 Mar;38(3):500-7. doi: 10.1016/j.humpath.2006.09.020.